Zydus granted Approval for macitentan tablets granted by USFDA

A wholly owned subsidiary of Cadila Healthcare Limited, Zydus Worldwide DMCC, has received tentative approval from the USFDA regarding macitentan 10 mg tablets .

The medication is helpful in treatment of pulmonary arterial hypertension. The manufacturing of drug will take place at CMO Umedica Laboratories Pvt Ltd, Vapi, Gujarat.

At present, The group has 287 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

  • Related Posts

    IPC releases draft NFI-2026 to promote rational use of medicines

    Ghaziabad:- The Indian Pharmacopoeia Commission (IPC) has taken a significant step toward strengthening public health systems with the draft release of the National Formulary of India (NFI) 2026, a comprehensive…

    Laser rescued an Imperiled Food Pipe in Sir Ganga Ram Hospital

    An Impacted Denture accidently  had lodged inside it New Delhi: In a remarkable medical achievement, doctors at Sir Ganga Ram Hospital successfully removed an impacted dental plate that had accidentally…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

    Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

    COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

    COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

    Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

    Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

    FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

    FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

    IPC releases draft NFI-2026 to promote rational use of medicines

    IPC releases draft NFI-2026 to promote rational use of medicines